
Surrozen (SRZN) Stock Forecast & Price Target
Surrozen (SRZN) Analyst Ratings
Bulls say
Surrozen is poised for success with its strong clinical-stage pipeline and unique approach to targeting the Wnt pathway in retinal diseases. The company's lead product candidate, SZN-8141, has shown promising preclinical efficacy and has incorporated both Wnt pathway activation and VEGF inhibition, potentially providing greater efficacy and durability compared to currently available treatments. With increasing potential for investors as the company nears IND submission for SZN-8141 and continues to advance its other pipeline candidates, we maintain a positive outlook on Surrozen's stock.
Bears say
Surrozen is a clinical-stage biotechnology company, with a product candidate focused on selectively modulating the Wnt pathway for tissue repair in various organs. However, the company has not yet reached the phase of IND submission and there are risks associated with achieving peak commercial revenue. While their preclinical successes in retinopathy models are promising, there remains an unmet need for durable treatments and key data metrics such as durability and adoption rates are yet to be proven in clinical trials. Additionally, competition from other companies with Wnt pathway targeting development such as Merck could hinder Surrozen's success.
This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.
Surrozen (SRZN) Analyst Forecast & Price Prediction
Start investing in Surrozen (SRZN)
Order type
Buy in
Order amount
Est. shares
0 shares